Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
- First patient dosed in France, expanding the DOMISOL study beyond Australia
- DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program
Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today announced dosing of the first patient in the European expansion of its DOMISOL Phase I/II clinical trial evaluating DT‑7012, a proprietary Treg‑depleting anti‑CCR8 monoclonal antibody, in patients with advanced solid tumors.
